AI and cryptocurrency scams are costing Americans billions, FBI reports
The fraud landscape has been changed by AI and cryptocurrency in a way that should concern organisations and individuals alike. Read more in my article on the Fortra blog. Continue reading →
Shuffle Board: Kendra Scott Taps CFO as Tapestry Expands Board
Kendra Scott announces former MLM executive Mike McMullen as CFO while Tapestry appoints Matt Madrigal to its board of directors. Continue reading →
Antwerp Oil Spill Adds to Pressure on Congested European Ports
A leak at the MSC PSA European Terminal halts vessel traffic for hours, with the Belgian port racing to restore full operations by Saturday. Continue reading →
All Hail the Seven-step PDRN Routine
An inside look at why a regenerative ingredient traditionally derived from salmon sperm is taking over beauty counters. Continue reading →
OOCL posts revenue decline in muted first quarter
The start to the year was largely unaffected by the Middle East conflict, but the lagging effect of high bunker fuel prices will be felt from the second quarter onward. Continue reading →
El Niño forecast suggests risk of low water levels along Panama Canal
As if the Strait of Hormuz and Red Sea haven’t caused enough concern for commercial shipping, Lars Jensen warns of the potential for weather-related disruptions once again at the canal by year-end. Continue reading →
Revised UP-NS merger application will address deficiencies, critics concerns
The railroads say they plan to file an updated merger application on April 30, addressing many of the complaints that caused regulators to deem their original application “incomplete.” Continue reading →
Pharma 50: The 50 best-selling drugs of FY2025
The headline fight in FY2025 pharma happened at the very top of the leaderboard, where Keytruda held the No. 1 brand slot even as Lilly’s tirzepatide and Novo’s semaglutide passed it at the molecule level. We covered that reshuffle in a separate analysis. Look past Keytruda, Mounjaro...
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s Keytruda (pembrolizumab) remained pharma’s No. 1 brand in FY2025 with $31.7 billion in sales. But it is no longer the industry’s top-selling medicine at the molecule level. Lilly’s tirzepatide franchise, spanning Mounjaro ($22.965 billion) and Zepbound ($13.542...